Merck & Co., Inc. Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Merck & Co., Inc. operates two primary segments: Pharmaceutical (human health) and Animal Health. The reporting period is characterized by significant business development activity, including major asset acquisitions, and the impact of patent expirations on key diabetes products.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Sales | $16,607 million | $15,806 million | $32,893 million | $31,335 million |
| Net (Loss) Income | $(1,335) million | $4,427 million | $(5,575) million | $9,506 million |
| Diluted EPS | $(0.54) | $1.76 | $(2.26) | $3.77 |
| Operating Cash Flow (6mo) | $9,288 million | $5,793 million | ||
| Free Cash Flow (6mo) | $7,404 million | $3,701 million | ||
| Total Debt | $53,906 million | $49,339 million | ||
| Cash & Equivalents | $6,849 million | $14,565 million | ||
| Gross Margin | 73.5% | 77.5% | 73.9% | 77.7% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 5% year-over-year in Q2 2026, driven by growth in Oncology (Keytruda, Welireg), Cardiometabolic (Winrevair), and Animal Health. This was partially offset by declines in Vaccines (Gardasil) and Diabetes (Januvia/Janumet) due to generic competition and market dynamics.
- Net Loss: The company reported a net loss of $1.3 billion in Q2 2026 compared to a net income of $4.4 billion in Q2 2025. This reversal is primarily due to $14.7 billion in non-cash R&D charges related to the acquisitions of Terns Pharmaceuticals ($5.7 billion) and Cidara Therapeutics ($9.0 billion), which were accounted for as asset acquisitions with no alternative future use.
- Cost Structure: Cost of sales increased 24% due to higher amortization of intangible assets, inventory write-downs, and restructuring costs. R&D expenses surged to $9.7 billion in Q2 2026 from $4.0 billion in Q2 2025.
- Liquidity: Cash and cash equivalents decreased significantly from $14.6 billion to $6.8 billion, reflecting heavy investment in acquisitions ($14.6 billion net cash used in investing activities for the six months ended June 30, 2026).
Guidance, Outlook, and Risks
- Acquisition Integration: Merck is integrating Terns (oncology) and Cidara (influenza prevention) into its pipeline. The company expects these assets to drive future growth despite the immediate earnings impact.
- Pricing and Policy: The company faces ongoing pricing pressure from the U.S. Inflation Reduction Act (IRA), including government price-setting for Januvia (effective Jan 2026) and Lenvima (effective Jan 2028). A new German health care reform law (GKV-BStabG) is expected to exert downward pressure on sales in Germany starting Jan 2027.
- Patent Expirations: Januvia and Janumet lost U.S. market exclusivity in May 2026, and Janumet XR in July 2026. The company expects a substantial portion of U.S. sales for these products to be lost to generic competition. Bridion also lost exclusivity in July 2026.
- Legal Contingencies: Significant litigation includes the Gardasil product liability settlement (finalized), ongoing Dr. Scholl's talc litigation, and a False Claims Act investigation regarding diversity, equity, and inclusion (DEI) programs. The company is also contesting IRS Notices of Proposed Adjustment regarding a one-time transition tax of approximately $1.3 billion plus penalties.
- Restructuring: The company is executing two restructuring programs (2024 and 2025) with estimated cumulative costs of $7.0 billion, aiming for $3.0 billion in annual cost savings by the end of 2027.
Investor Verification Checklist
- Acquisition Accounting: Verify the treatment of the $14.7 billion R&D charges for Terns and Cidara as non-cash, non-recurring items impacting GAAP earnings but not cash flow.
- Keytruda Performance: Monitor sales trends for Keytruda and Keytruda Qlex, specifically the impact of new indications and potential biosimilar erosion in international markets.
- Diabetes Franchise Decline: Assess the magnitude of sales erosion for Januvia and Janumet following U.S. patent expiration and the effectiveness of the IRA price negotiation.
- Liquidity Position: Review the reduction in cash reserves from $14.6 billion to $6.8 billion and the company's ability to fund future dividends and buybacks while maintaining investment in R&D.
- Legal Exposure: Track the status of the IRS audit regarding the transition tax and the outcome of the Gardasil settlement implementation.